Sign In
Buy CVKD
$4.19
-0.160 (-3.68%)
At Close: Jun 03, 2026
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
09:00am, Wednesday, 03'rd Jun 2026
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX cou
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
04:30pm, Tuesday, 19'th May 2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunity E
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
08:00am, Thursday, 12'th Mar 2026
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thromboti
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
08:00am, Monday, 02'nd Mar 2026
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., Ma
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update
01:16am, Monday, 02'nd Mar 2026
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 22.1% in January
02:44am, Tuesday, 17'th Feb 2026
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 71,276 sh
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current a
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock
04:52am, Friday, 02'nd Jan 2026
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $6.
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
08:00am, Tuesday, 30'th Dec 2025
PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity. Others step in because the situation has become unsustainable, and someone has to fi
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
08:00am, Monday, 29'th Dec 2025
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods.
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update
04:47am, Sunday, 28'th Dec 2025
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 61,6
